152 related articles for article (PubMed ID: 19038009)
1. Overexpression of RhoA enhances peritoneal dissemination: RhoA suppression with Lovastatin may be useful for ovarian cancer.
Horiuchi A; Kikuchi N; Osada R; Wang C; Hayashi A; Nikaido T; Konishi I
Cancer Sci; 2008 Dec; 99(12):2532-9. PubMed ID: 19038009
[TBL] [Abstract][Full Text] [Related]
2. HMG-CoA reductase inhibitor lovastatin causes reversible cytoskeleton perturbation by RhoA signalling suppression in peritoneal cell line Met5A.
Suzuki N; Imai A
J Obstet Gynaecol; 2010 May; 30(4):404-7. PubMed ID: 20455727
[TBL] [Abstract][Full Text] [Related]
3. Lovastatin suppresses invasiveness of anaplastic thyroid cancer cells by inhibiting Rho geranylgeranylation and RhoA/ROCK signaling.
Zhong WB; Liang YC; Wang CY; Chang TC; Lee WS
Endocr Relat Cancer; 2005 Sep; 12(3):615-29. PubMed ID: 16172195
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of epidermal growth factor-induced RhoA translocation and invasion of human pancreatic cancer cells by 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Nakamura H
Cancer Res; 2001 Jun; 61(12):4885-91. PubMed ID: 11406567
[TBL] [Abstract][Full Text] [Related]
5. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line.
Ghosh PM; Ghosh-Choudhury N; Moyer ML; Mott GE; Thomas CA; Foster BA; Greenberg NM; Kreisberg JI
Oncogene; 1999 Jul; 18(28):4120-30. PubMed ID: 10435593
[TBL] [Abstract][Full Text] [Related]
6. Adenovirus-mediated calponin h1 gene therapy directed against peritoneal dissemination of ovarian cancer: bifunctional therapeutic effects on peritoneal cell layer and cancer cells.
Ogura T; Kobayashi H; Ueoka Y; Okugawa K; Kato K; Hirakawa T; Hashimoto S; Taniguchi S; Wake N; Nakano H
Clin Cancer Res; 2006 Sep; 12(17):5216-23. PubMed ID: 16951241
[TBL] [Abstract][Full Text] [Related]
7. WWOX gene expression abolishes ovarian cancer tumorigenicity in vivo and decreases attachment to fibronectin via integrin alpha3.
Gourley C; Paige AJ; Taylor KJ; Ward C; Kuske B; Zhang J; Sun M; Janczar S; Harrison DJ; Muir M; Smyth JF; Gabra H
Cancer Res; 2009 Jun; 69(11):4835-42. PubMed ID: 19458077
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin-induced PC-12 cell differentiation is associated with RhoA/RhoA kinase pathway inactivation.
Fernández-Hernando C; Suárez Y; Lasunción MA
Mol Cell Neurosci; 2005 Aug; 29(4):591-602. PubMed ID: 15951198
[TBL] [Abstract][Full Text] [Related]
9. Role of Rho protein in lovastatin-induced breakdown of actin cytoskeleton.
Koch G; Benz C; Schmidt G; Olenik C; Aktories K
J Pharmacol Exp Ther; 1997 Nov; 283(2):901-9. PubMed ID: 9353412
[TBL] [Abstract][Full Text] [Related]
10. Effect of interleukin-7 gene transfection into ovarian carcinoma cell line SKOV3 in vitro and in vivo.
Xie X; Ye DF; Chen HZ; Lu WG; Fu YF; Cheng B; Zhu H
Gynecol Oncol; 2004 Feb; 92(2):578-85. PubMed ID: 14766250
[TBL] [Abstract][Full Text] [Related]
11. Alendronate inhibits intraperitoneal dissemination in in vivo ovarian cancer model.
Hashimoto K; Morishige K; Sawada K; Tahara M; Kawagishi R; Ikebuchi Y; Sakata M; Tasaka K; Murata Y
Cancer Res; 2005 Jan; 65(2):540-5. PubMed ID: 15695397
[TBL] [Abstract][Full Text] [Related]
12. Tocotrienols potentiate lovastatin-mediated growth suppression in vitro and in vivo.
McAnally JA; Gupta J; Sodhani S; Bravo L; Mo H
Exp Biol Med (Maywood); 2007 Apr; 232(4):523-31. PubMed ID: 17392488
[TBL] [Abstract][Full Text] [Related]
13. Synergistic anti-tumor efficacy of lovastatin and protein kinase C-beta inhibitor in hepatocellular carcinoma.
Kim W; Yoon JH; Kim JR; Jang IJ; Bang YJ; Kim YJ; Lee HS
Cancer Chemother Pharmacol; 2009 Aug; 64(3):497-507. PubMed ID: 19096848
[TBL] [Abstract][Full Text] [Related]
14. Proapoptotic and antitumor activities of the HMG-CoA reductase inhibitor, lovastatin, against Dalton's lymphoma ascites tumor in mice.
Ajith TA; Harikumar KB; Thasna H; Sabu MC; Babitha NV
Clin Chim Acta; 2006 Apr; 366(1-2):322-8. PubMed ID: 16380106
[TBL] [Abstract][Full Text] [Related]
15. RNA interference-mediated silencing of the phosphatidylinositol 3-kinase catalytic subunit attenuates growth of human ovarian cancer cells in vitroand in vivo.
Zhang X; Deng HX; Zhao X; Su D; Chen XC; Chen LJ; Wei YQ; Zhong Q; Li ZY; He X; Yi T
Oncology; 2009; 77(1):22-32. PubMed ID: 19440000
[TBL] [Abstract][Full Text] [Related]
16. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma.
Kawajiri H; Yashiro M; Shinto O; Nakamura K; Tendo M; Takemura S; Node M; Hamashima Y; Kajimoto T; Sawada T; Ohira M; Hirakawa K
Clin Cancer Res; 2008 May; 14(9):2850-60. PubMed ID: 18451253
[TBL] [Abstract][Full Text] [Related]
17. 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis.
Kusama T; Mukai M; Iwasaki T; Tatsuta M; Matsumoto Y; Akedo H; Inoue M; Nakamura H
Gastroenterology; 2002 Feb; 122(2):308-17. PubMed ID: 11832446
[TBL] [Abstract][Full Text] [Related]
18. Lovastatin-induced RhoA modulation and its effect on senescence in prostate cancer cells.
Lee J; Lee I; Park C; Kang WK
Biochem Biophys Res Commun; 2006 Jan; 339(3):748-54. PubMed ID: 16316623
[TBL] [Abstract][Full Text] [Related]
19. Prolonged survival and decreased invasive activity attributable to dipeptidyl peptidase IV overexpression in ovarian carcinoma.
Kajiyama H; Kikkawa F; Suzuki T; Shibata K; Ino K; Mizutani S
Cancer Res; 2002 May; 62(10):2753-7. PubMed ID: 12019149
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of lysophosphatidic acid-induced RhoA activation and tumor cell invasion by 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors.
Kusama T; Mukai M; Ayaki M; Imamura F; Tatsuta M; Matsumoto Y; Nakamura H; Inoue M
Int J Oncol; 2003 Oct; 23(4):1173-8. PubMed ID: 12964001
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
